In Situ Hybridization: Market Shares, Strategies, and Forecasts, Worldwide, 2018 to 2024

Published: Mar, 2018 | Pages: 242 | Publisher: WinterGreen Research
Industry: Biotechnology | Report Format: Electronic (PDF)

The Global In Situ Hybridization Market is estimated to develop at a substantial CAGR of 7.8% for the duration 2017 to 2024. The markets are composed to attain ongoing progress because In Situ Hybridization is utilized in analytical circumstances to investigate solo cells inside soft tissue. Handling of solo cell diagnostics in actual phase is inspiring combined commercial efforts. Dropping prices of business management is an important advantage.

The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024 2017. The factors such as growing analysis, increasing occurrence & frequency of cancer, technical progressions in therapeutics, growing government resourcefulness all over the world are projected to motivate the progress of the market during the approaching years. In Situ Hybridization [ISH] is a category of hybridization. It practices balancing of RNA, DNA or else altered nucleic acids element, for example probe; to restrict a precise RNA sequence or DNA sequence, in a percentage or a section of soft tissue [in situ], or, if the soft tissue is sufficient minor such as Drosophila embryos , plant seeds, in the complete soft tissue [complete base ISH], in cells, and in Circulating Tumor Cells [CTCs].

In situ Hybridization [ISH] is an influential method for restricting exact nucleic acid objectives in static tissues and cells, permitting operators to find chronological and three-dimensional information regarding genetic factor look and genetic loci. On the other hand, the simple workflow of In Situ Hybridization is, like that of spot hybridizations. The nucleic acid investigation is manufactured; categorized, cleansed, and strengthened by means of the exact target. The variance is the larger sum of data increased by imagining the consequences inside the soft tissue.

The In Situ Hybridization market on the source of Area with respect to Trades in terms of intake, Profits, Market stake and Development percentage in these areas, for the duration of the prediction could span North America, Europe, Asia-Pacific, Middle East & Africa, and South America.

The statement revises Trades in terms of intake of In Situ Hybridization in the international market; particularly in of North America, Europe, Japan, India, China, and Southeast Asia. It concentrates on the topmost companies operating in these regions. Some of the important companies operating in the field are BioTechne / Advanced Cell Diagnostics [ACD], Merck KGaA, PerkinElmer, Abbott Laboratories, Thermo Fisher Scientific, BioGenex Laboratories, Qiagen / Exiqon A/S, Agilent Technologies, F. Hoffmann-La Roche AG, and Leica Bio systems Nussloch GmbH.

Worldwide markets are poised to achieve continuing growth as In Situ Hybridization is used in diagnostic situations to analyze single cells inside tissue. Managing single cell diagnostics in real time, encouraging collaborative business efforts. Lowering transaction management costs is a key benefit.

In situ hybridization (ISH) is a type of hybridization that uses a labeled complementary DNA, RNA or modified nucleic acids strand (i.e., probe) to localize a specific DNA or RNA sequence in a portion or section of tissue (in situ), or, if the tissue is small enough (e.g., plant seeds, Drosophila embryos), in the entire tissue (whole mount ISH), in cells, and in circulating tumor cells (CTCs).

Advances in RNA in situ hybridization transform molecular detection with morphological context enabling new applications. Scientists use RNA ISH to extract data dimensions.

Immunohistochemistry (IHC) and RNA in situ Hybridization are widely used technologies sharing the unique capacity to analyze a marker at the single cell level while preserving the morphological context. In different situations, IHC and ISH are used in conjunction to validate data or provide complementary information.

In situ hybridization (ISH) is a powerful technique for localizing specific nucleic acid targets within fixed tissues and cells, allowing users to obtain temporal and spatial information about gene expression and genetic loci. While the basic workflow of ISH is similar to that of blot hybridizations-the nucleic acid probe is synthesized, labeled, purified, and annealed with the specific target-the difference is the greater amount of information gained by visualizing the results within the tissue.

The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024 2017. CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.

Companies Profiled

Market Leaders

• Leica Biosystems Nussloch GmbH
• Thermo Fisher Scientific
• F. Hoffmann-La Roche AG
• Abbott Laboratories
• Agilent Technologies
• PerkinElmer
• Qiagen / Exiqon A/S
• Merck KGaA
• BioGenex Laboratories
• BioTechne / Advanced Cell Diagnostics (ACD)

Key Topics

• In Situ Hybridization
• Molecular Diagnostics
• Cervical Cancer Stain
• Fish Steps Reduction
• Fluorescence In Situ Hybridization (FISH)
• In Situ Hybridization (ISH)
• FISH Probe Kit
• Cancer
• Chromosonal Abnormalities
• Infectious Diseases
• Inflammatory Diseases
• Fluorescence In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Human Genetic Tests
• Microbial Tests
• In Vitro Diagnostics
• System for the Analysis of Solid Tumors
• Hybridization Technique
• Detection of Long Non-
• Coding DNA
• Coding RNA

 Table of Contents

US In situ Hybridization Executive Summary 15
In Situ Hybridization (ISH) 15

1. United States In Situ Hybridization ISH Market Definition and Market Dynamics 16
1.1 US In situ Hybridization Market Overview 16
1.1.1 Antibody Challenges and Validation 16
1.2 Scope of In situ Hybridization in Inflammation 17
1.2.1 RNAscope® Applications 17

2. In-Situ Hybridization Market Shares and Market Forecasts 20
2.1 In-Situ Hybridization Market Driving Forces 20
2.1.1 Identification of Cytokines and their Cellular Origins 21
2.1.2 Detection of Long Non-Coding RNA (lncRNA) in Inflammatory Diseases 21
2.1.3 Role of Inflammatory Pathways During Carcinogenesis 22
2.1.4 Therapeutic Potential Of Secreted Proteins In Inflammatory Diseases 22
2.1.5 Dual ISH-IHC Detect Cytokines During Inflammatory Responses 22
2.2 In Situ Hybridization Market Shares 24
2.2.1 Roche 25
2.2.2 Abbott Molecular 25
2.2.3 Advanced Cell Diagnostics 25
2.2.4 PerkinElmer In Situ Hybridization Market Driving Forces 26
2.2.5 In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments 27
2.3 In Situ Hybridization Market Forecasts 29
2.3.5 In Situ Hybridization Market Segments, Units and Kits, Dollars and Percent, US, 29
2.4 In situ Hybridization Market Segments 31
2.4.1 In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017 32
2.4.2 Fluorescence (FISH) and Chromogenic (CISH) Detection 33
2.4.3 ISH Applications 36
2.4.4 Multiplex Fluorescence In Situ Hybridization (FISH) 36
2.4.5 Fluorescence In Situ Hybridization (FISH) 37
2.4.6 Cancer Drug Market 40
2.4.7 Chronic Lymphocytic Leukemia (CLL) 40
2.4.8 In-Situ Hybridization Cancer Diagnosis, Cytology, Infectious Disease Molecular Diagnostic 42
2.1.6 In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies 47
2.5 In-Situ Hybridization Pricing 54
2.5.1 miRCURY LNA miRNA Detection Probes 54
2.5.2 Price and Availability 58
2.6 In-Situ Hybridization Geographical Analysis 61

3 In-Situ Hybridization Research and Technology 68
3.1 Hybridization Technique 68

4 In-Situ Hybridization Company Profiles 69
4.1 Abbott Laboratories 69
4.1.1 Abbott Laboratories Market Categorization 69
4.1.2 In Situ Hybridization Product Category, Application and Specification 70
4.1.3 Abbott Laboratories Vysis Chronic Lymphocytic Leukemia (CLL) FISH Probe Kit (IVD) 71
4.1.4 Vysis CLL FISH Probe Kit Contents 72
4.1.5 Acupath Laboratories Test For Detecting Bladder Cancer Uses Probes from Abbott Molecular 74
4.1.6 Abbott Laboratories Barrett’s Esophagus FISH 75
4.1.7 Abbott Molecular Vysis CLL FISH Probe Kit | 77
4.1.8 Abbott Laboratories Revenue 77
4.1.9 Abbott Laboratories ThermoBrite System 81
4.1.10 Abbott Laboratories User Programmable Settings 82
4.1.11 Abbott Laboratories Vysis FISH Chromosome Search 83
4.1.12 Abbott Laboratories Molecular Diagnostics 84
4.1.13 Abbott Diagnostic Products 85
4.2 Acupath Laboratories 87
4.2.1 Acupath Laboratories Barrett’s Esophagus FISH 88
4.3 Agilent Technologies 88
4.3.1 Agilent CGH & CGH+SNP Microarrays 91
4.3.2 Agilent Technologies Revenue 91
4.3.3 Agilent Diagnostics and Genomics 93
4.4 Bio-Techne / ACD 96
4.4.1 Bio-Techne ACD RNAscope Widely Used In-Situ Hybridization Technique 97
4.4.2 Bio-Techne Revenue 98
4.4.3 Biotechne US Regional Analysis 101
4.4.4 Advanced Cell Diagnostics 102
4.5 F. Hoffmann-La Roche AG 102
4.5.1 Roche Gene Amplification by Fluorescence In Situ Hybridization 104
4.5.2 Roche Automated RNA isolation 105
4.5.3 Roche Fluorescence In Situ Hybridization (FISH) 105
4.5.4 Roche Agreement with Merck Millipore Sigma 106
4.5.5 Roche Immuno Diagnostics 108
4.5.6 F. Hoffmann-La Roche AG Revenue 109
4.5.7 Roche Buys Flatiron Health Leader In Oncology-Specific Electronic Health Record (EHR) Software 114
4.6 Danaher / Leica Biosystems Nussloch GmbH 115
4.6.1 Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments 116
4.6.2 Leica Biosystems Nussloch GmbH Revenue 122
4.6.3 Danaher Geographical Revenue 124
4.7 Thermo Fisher Scientific 125
4.7.1 Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) 125
4.7.2 Chromogenic In Situ Hybridization (CISH) 128
4.7.3 Thermo Fisher Scientific Revenue 133
4.8 Merck KGaA 134
4.9 PerkinElmer 135
4.9.1 PerkinElmer Stain 144
4.9.2 Perkin Elmer Revenue 146
4.10 Qiagen / Exiqon A/S 150
4.10.1 Qiagen’s GeneReader NGS System 153
4.10.2 Polygenetic Mutations Drive Cancer 153
4.10.3 Qiagen Revenue 154
4.11 BioGenex Laboratories 155
4.11.1 BioGenex Fully-Automated Molecular Pathology Workstation 156
4.11.2 BioGenex Boosts Genome Research and Diagnostics - BioGenex US 159
4.11.3 BioGenex Antibodies for Cancer Diagnosis 161
4.11.4 BioGenex PMS2 161
CK5 162
4.11.5 eFISHiency System for the Analysis of Solid Tumors - BioGenex US 163
4.12 Bio SB 165
4.12.1 Bio SB Zytovision Molecular Diagnostics 165
4.13 Bio-Techne / Advanced Cell Diagnostics (ACD) 167

5 Summary and Conclusions 172
5.1 Analyze A Marker At The Single Cell Level 172
5.2 Advances in RNA In Situ Hybridization 172

6 Appendix A: List Of Nucleic Acid-Based Tests 173
6.1 List: Nucleic Acid-Based Tests Approved by US Center for Devices and Radiological Health 173
6.1.1 List of Human Genetic Tests 174
6.1.2 List of Microbial Tests 191
6.2 In Vitro Diagnostics 233
WinterGreen Research, 235
WinterGreen Research Methodology 236
WinterGreen Research Process 237
Market Research Study 238
WinterGreen Research Global Market Intelligence Company 239

List of Figures

Figure 1. In Situ Hybridization Market Shares, Dollars, US, 2016 and 2017 24
Figure 2. In Situ Hybridization Market Driving Forces 26
Figure 3. In Situ Hybridization Market Shares, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017 27
Figure 4. In Situ Hybridization Market Shares, $ per Unit and $ per Kit, Dollars and Percent, US, 2017 28
Figure 5. In Situ Hybridization Market Segments, Unit Shipments and Kit Shipments, Units and Dollars, US, 2017 29
Figure 6. In Situ Hybridization Market Segments, $ per Unit and $ per Kit, Dollars and Percent, US, 2017 30
Figure 7. In Situ Hybridization Market Shares, Dollars, Worldwide, 2012 to 2017 32
Figure 8. In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2012 to 2017 33
Figure 9. In Situ Hybridization Market Segments, Fluorescence In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH), US, 2017 to 2024 34
Figure 10. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods 35
Figure 11. Diagnostics Growth 42
Figure 12. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Dollars, US, 2012 to 2017 43
Figure 13. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Dollars, US, 2017 to 2024 44
Figure 14. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Percent, US, 2017 to 2024 45
Figure 15. In Situ Hybridization Market Segments, Cancer, Chromosonal Abnormalities, Infectious Diseases, Percent, US, 2012 to 2017 45
Figure 16. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2012 to 2017 47
Figure 17. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Dollars, US, 2017 to 2024 48
Figure 18. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2012 to 2017 49
Figure 19. In Situ Hybridization Market Segments, Diagnostic Laboratories, Academic & Research Institutes, Contract Research Organizations, and Pharmaceutical & Biotechnology Companies, Percent, US, 2017 to 2024 50
Figure 20. 575 Million People with Autoimmune Disease 51
Figure 21. PerkinElmer Assays for Autoimmune Disease 52
Figure 22. PerkinElmer Diagnostics 53
Figure 23. PerkinElmer In Situ Hybridization 57
Figure 24. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2012 – 2017 63
Figure 25. In Situ Hybridization Regional Analysis, US: West, Rocky Mountain, Southwest, Midwest, South, Middle Atlantic, New York and New England, Percent, 2017 - 2024 65
Figure 26. Abbott Laboratories Vysis CLL FISH Probe Kit Probe Info 71
Figure 27. Abbott Laboratories Vysis CLL FISH Probe Kit Contents 72
Figure 28. Abbott Laboratories Vysis CLL FISH Probe Kit includes LSI 72
Figure 29. Abbott Vysis CLL FISH Probe Kit 73
Figure 30. Abbott Laboratories Segment Sales, 2017 78
Figure 31. Abbott Segment Sales 2015-2017 79
Figure 32. Abbott Geographical Revenue 80
Figure 33. Abbott Laboratories ThermoBrite System 81
Figure 34. Abbott Laboratories ThermoBrite System Functions 82
Figure 35. Abbott Laboratories Molecular Testing 84
Figure 36. Abbott Diagnostic Product Target Markets 85
Figure 37. Abbott Diagnostic Principal Products 86
Figure 38. In Situ Hybridization Detection System: Agilent Product Area: Standard Nucleic Acid Detection System 88
Figure 39. PNA ISH Detection Kit Product Area: PNA Probes & Detection System 90
Figure 40. Roche RNA Isolation Kit 105
Figure 41. Merck MilliporeSigma and Sigma-Aldrich and Roche Offerings 107
Figure 42. Key points of the Roche Merc agreement include: 107
Figure 43. Roche Immuno Diagnostics DISCOVERY XT 108
Figure 44. Roche DISCOVERY XT Research Instrument Functions 109
Figure 45. F. Hoffmann-La Roche AG Sales 110
Figure 46. Roche by the Metrics 112
Figure 47. F. Hoffmann-La Roche AG Pharmaceutical Sales 113
Figure 48. Danaher Brands 116
Figure 49. Leica Biosystems Bond III Technical Specifications 117
Figure 50. Leica Biosystems Nussloch GmbH BOND IHC/ISH Instruments 118
Figure 51. Leica SCN400 Slide Scanner Features 119
Figure 52. Leica BOND Ready-To-Use Antibodies (No Mixing, Titration Or Dilution) 120
Figure 53. Leica Biosystems 121
Figure 54. Danaher Segment Revenue 123
Figure 55. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) Positioning 125
Figure 56. Thermo Fisher Scientific Fluorescence In Situ Hybridization (FISH) In Situ Hybridization (ISH) Technologies 126
Figure 57. Thermo Fisher Scientific Characteristics of In Situ Hybridization Methods 127
Figure 58. 5.7.1 Thermo Fisher Scientific EVOS Cell Imaging Systems 129
Figure 59. Thermo Fisher Scientific Fluorescence Systems 130
Figure 60. Thermo Fisher Scientific Cell Analysis 131
Figure 61. Thermo Fisher Scientific Imaging Portfolio Components 132
Figure 62. Thermo Fisher Scientific Revenue 133
Figure 63. PerkinElmer In Situ Hybridization 136
Figure 64. PerkinElmer In Situ Hybridization 137
Figure 65. PerkinElmer In Situ Hybridization 139
Figure 66. PerkinElmer Financials at a Glance 140
Figure 67. PerkinElmer Diagnostics Revenue 141
Figure 68. PerkinElmer in situ hybridization Expanding Diagnostics Market Reach and Global Impact 142
Figure 69. PerkinElmer Diagnostics 143
Figure 70. PerkinElmer Stain 144
Figure 71. Perkin Elmer Revenue 146
Figure 72. PerkinElmer offers Ultra-Sensitive And Specific Mirna Detection By In Situ Hybridization (ISH) Functions 149
Figure 73. miRCURY LNA miRNA Detection Probes 151
Figure 74. BioGenex Performance Systems 156
Figure 75. BioGenex Product Areas 157
Figure 76. BioGenex Performance Systems / BioGenex Flagship Products 157
Figure 77. BioGenex Customers 158
Figure 78. Figure: Colon Carcinoma stained with PMS2 (clone EP51),Staining in FFPE tisues, using DAB chromogen and BioGenex Polymer-HRP Detection System. 162
Figure 79. BioGenex Cervical Cancer Stained with Anti-Human CK-5 (clone EP24),Staining in FFPE Tissues, Using DAB Chromogen and Polymer-HRP Detection System 163
Figure 80. BioGenex Fish Steps Reduction 164
Figure 81. BioGenex eFISHiency System Reduces Hands-On Processing Time To 30 Minutes 165
Figure 82. Bio SB Zytovision Molecular Diagnostics 165
Figure 83. Bio-Techne / ACD 170